In recent trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 0.78 million shares changing hands at last check today with its beta currently measuring 0.67. Company’s recent per share price level of $0.96 trading at -$0.04 or -4.05% at last check today assigns it a market valuation of $176.99M. That most recent trading price of NKTR’s stock is at a discount of -101.04% from its 52-week high price of $1.93 and is indicating a premium of 34.37% from its 52-week low price of $0.63.

For Nektar Therapeutics (NKTR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.

Nektar Therapeutics (NASDAQ:NKTR) trade information

Upright in the red during last session for losing -4.05%, in the last five days NKTR remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.96 price level, adding 11.11% to its value on the day. Nektar Therapeutics’s shares saw a change of 3.17% in year-to-date performance and have moved 31.26% in past 5-day. Nektar Therapeutics (NASDAQ:NKTR) showed a performance of 6.14% in past 30-days.

Wall Street analysts have assigned a consensus price target of 18.5 to the stock, which implies a rise of 94.81% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -525.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -525.0% for stock’s current value.

Nektar Therapeutics (NKTR) estimates and forecasts

This year revenue growth is estimated to rise 17.53% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 36.65M for the same. And 6 analysts are in estimates of company making revenue of 22.39M in the next quarter. Company posted 23.89M and 21.64M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 50.60% while estimates for its earnings growth in next 5 years are of 21.38%.

Nektar Therapeutics (NASDAQ:NKTR)’s Major holders

DEEP TRACK CAPITAL, LP is the top institutional holder at NKTR for having 17.88 million shares of worth $22.17 million. And as of 2024-06-30, it was holding 8.5599 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 15.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7823 of outstanding shares, having a total worth of $18.79 million.

On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 9.4 shares of worth $8.99 million or 5.10% of the total outstanding shares. The later fund manager was in possession of 5.72 shares on Sep 30, 2024, making its stake of worth around $5.47 million in the company or a holder of 3.10% of company’s stock.